Bridging the Gap: Controversies in Perioperative Anticoagulation Management

<p>Ming May Zhang, PharmD (Twitter: <a href='https://twitter.com/amayzhanggg'>@amayzhanggg</a>) reviews key bleeding and thromboembolic risks that should be considered in the perioperative setting, describes the current evidence for perioperative warfarin management in atrial fibrillation, venous thromboembolism, and mechanical heart valves and discusses patient- and disease-specific risk factors that may impact decisions regarding perioperative bridging.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>